The business model of Medtronic PLC primarily focuses on the development, manufacturing, and distribution of medical technology devices and solutions. Medtronic specializes in the fields of cardiac and vascular therapies, minimally invasive therapies, restorative therapies, and diabetes management. The company aims to improve patient outcomes by providing innovative and high-quality products to healthcare professionals worldwide. Medtronic's business model revolves around collaborating with healthcare providers, patients, and other stakeholders to create innovative solutions that address unmet medical needs. Through strategic partnerships and continuous research and development, Medtronic strives to enhance patient care and improve the overall healthcare landscape.

Medtronic PLC is primarily active in the healthcare industry.

The main competitors of Medtronic PLC in the market are Abbott Laboratories, Boston Scientific Corporation, and Johnson & Johnson.

Medtronic PLC is a renowned global medical technology company headquartered in Dublin, Ireland. It was founded in 1949 by Earl Bakken and Palmer Hermundslie, initially operating as a medical equipment repair shop. Over the years, Medtronic evolved to become a leader in healthcare solutions, focusing on innovative medical devices and therapies. The company specializes in areas such as cardiovascular, diabetes, neurological, and spine care technologies, serving patients in more than 150 countries worldwide. With a rich history of transformative medical breakthroughs, Medtronic's commitment to improving patient outcomes and advancing healthcare is well-recognized in the industry.

Medtronic PLC, a leading medical technology company, has achieved several significant milestones. The company pioneered the development of the first battery-powered wearable external pacemaker in 1957, revolutionizing cardiac healthcare. In 1960, Medtronic introduced the first implantable pacemaker, a remarkable breakthrough in medical devices. Another notable achievement came in 1978 when Medtronic introduced the first insulin pump for diabetes management, improving the lives of millions. Medtronic has also made advancements in minimally invasive surgery with its innovative instruments and techniques. With a strong focus on research and development, Medtronic continues to push boundaries in healthcare technology, enhancing patient outcomes worldwide.

Medtronic PLC is primarily present in various countries and regions worldwide. Some of the key markets where Medtronic operates include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including China, Japan, and Australia), and Latin America. With a widespread global presence, Medtronic leverages its network to deliver innovative medical technologies and therapies to patients and healthcare professionals across different geographies. This multinational presence enables Medtronic PLC to serve a diverse range of markets and collaborate with healthcare partners to improve patient outcomes and enhance the delivery of healthcare services globally.

Medtronic PLC represents values of integrity, collaboration, and innovation. With a strong corporate philosophy focused on improving healthcare, Medtronic strives to create medical technologies that benefit patients worldwide. The company's mission is to alleviate pain, restore health, and extend lives through their innovative medical solutions. Medtronic believes in putting patients first and working together with healthcare professionals to develop cutting-edge therapies. They are dedicated to delivering high-quality products and services with utmost transparency and ethical practices. Medtronic's commitment to excellence and patient-centric approach has made it a leading global provider in the medical technology space.

Analysts currently set an average price target of 113,25 USD for the Medtronic stock (median: 114,64 USD), implying +38,1 % versus the latest price. The consensus is based on 35 analyst ratings.

Medtronic Analytikers kursmål 2026

38 analysts currently rate the Medtronic stock: 24 recommend buying, 13 holding and 1 selling.

Medtronic Analytikers kursmål 2026

Converted at the current exchange rate, the Medtronic share trades at 73,94 EUR (84,22 USD).

The Medtronic share (MDT) is listed on 11 stock exchanges, including: NYSE (MDT), XETRA (2M6.DE), Frankfurt (2M6.F), München (2M6.MU), Düsseldorf (2M6.DU), Hamburg (2M6.HM), London (0Y6X.L), London (0Y6X.L).

Medtronic PLC is a leading company in the medical technology industry and specializes in offering innovative and advanced therapies for a variety of diseases. The company was founded in 1949 by Earl Bakken and Palmer Hermundslie in Minneapolis, USA, and has since grown into a multinational corporation headquartered in Dublin, Ireland. Medtronic's business model is based on four main divisions: Cardiovascular Medicine, Diabetes, Neuromodulation, and Surgery. In the cardiovascular medicine division, the company offers a wide range of products and therapies for cardiovascular diseases and vascular constrictions. These include implantable pacemakers and defibrillators, stents for the treatment of narrowing in the heart arteries, and systems for monitoring heart rhythm. These products are an important part of medical care for people with severe cardiovascular diseases. In the diabetes division, Medtronic offers a range of insulin pumps and sensors that help people with type 1 diabetes or type 2 diabetes control their blood sugar levels. These technologies enable patients to receive more precise and personalized insulin therapy and can prevent serious complications such as gangrene and stroke. Medtronic's neuromodulation division focuses on the development of systems for the treatment of chronic pain, disorders of the nervous system, and neurological diseases. This includes implantable devices such as spinal cord stimulators that send electrical signals to the nervous system and can block pain stimuli. These devices can significantly improve the lives of patients with neuropathic pain or other conditions. Medtronic's surgery division offers products and technologies to support surgeons in complex procedures. These include cutting and coagulation instruments, surgical navigation systems, and products for bone and tissue regeneration. These products help improve patient outcomes and optimize surgical results. Medtronic is also active in various other areas, including respiratory diseases, urology, and infusion systems. The company focuses on creating innovative solutions that improve patient care and increase patients' quality of life. The focus on research and development is an important part of Medtronic's business model and drives continuous innovation in the field of medical technology. Overall, Medtronic is a company that focuses on the development and manufacture of innovative products and services that contribute to improving healthcare worldwide. The various divisions of the company work together in harmony to create innovations that improve the treatment and quality of life for patients.

omsetningen for Medtronic er 36,36 Mrd. USD. Denne verdien er basert på nåværende regnskapstall og gjenspeiler selskapets forretningsutvikling.

gevinsten for Medtronic er 4,80 Mrd. USD. Nettoresultatet viser selskapets lønnsomhet etter fradrag av alle kostnader.

Pris-til-inntjening-ratioen (P/E) for Medtronic er for tiden 22,60. P/E-ratioen sammenligner dagens aksjekurs med inntjening per aksje og hjelper investorer med å vurdere verdisetningen av Medtronic-aksjen.

Pris-til-salg-ratioen (P/S) for Medtronic er for tiden 2,98. P/S-ratioen sammenligner markedskapitalisering med årlig omsetning og fungerer som en verdisettelsesindiktor for Medtronic-aksjen.

Eulerpool Quality Score for Medtronic er 6/10.

ISIN for Medtronic er IE00BTN1Y115. ISIN (International Securities Identification Number) er en globalt unik identifikator for verdipapirer.

WKN for Medtronic er A14M2J. WKN (Wertpapierkennnummer) er et seks-sifret tysk verdipapirnummer.

Tickeren for Medtronic er MDT. Tickersymbolet brukes til å handle Medtronic-aksjer på børsen.

I løpet av de siste 12 månedene betalte Medtronic utbytte på 2,84 USD . Dette tilsvarer en utbytteavkastning på ca. 3,37 %. For de kommende 12 månedene forventes Medtronic å betale utbytte på 2,96 USD.

Utbytteavkastningen til Medtronic er for tiden 3,37 %.

Medtronic betaler utbytte som utdeles i månedene , , , .

Medtronic betalte utbytte hvert år de siste 36 årene.

For de kommende 12 månedene forventes utbytte på 2,96 USD. Dette tilsvarer en utbytteavkastning på 3,61 %.

Medtronic er klassifisert i sektoren 'Helse'.

For å motta det siste utbyttet fra Medtronic fra på 0,71 USD, måtte du ha aksjen i porteføljen før ex-datoen den .

Det siste utbyttet ble utbetalt den .

I året 2025 ble det utdelt 2,8 USD i utbytte fra Medtronic.

Utbyttene fra Medtronic utdeles i USD.